Grifols, a Spanish pharmaceutical company, remains confident that its planned stake sale in China will proceed as scheduled, despite recent speculation raised by the Gotham City report. The report, issued by Gotham City Research, raised concerns regarding Grifols' financial stability and questioned the company's operations in China. However, Grifols has reassured investors that it is committed to the sale and remains optimistic about the growth potential in the Chinese market.
Gotham City Research is known for releasing controversial reports that often lead to sharp declines in stock prices. In this instance, its report on Grifols triggered a temporary drop in the company's shares. Nevertheless, Grifols has responded swiftly and firmly, dismissing the allegations made in the report and reiterating its strong financial position.
